Interleukin-1 regulates CXCL8 release and influences disease outcome in response to streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages by Marriott, H. M. et al.
promoting access to White Rose research papers 
   
White Rose Research Online 
eprints@whiterose.ac.uk 
 
 
 
Universities of Leeds, Sheffield and York 
http://eprints.whiterose.ac.uk/ 
 
 
 
This is an author produced version of a paper published in Infection and 
Immunity. 
 
 
White Rose Research Online URL for this paper: 
http://eprints.whiterose.ac.uk/43771  
 
 
 
Published paper 
 
Marriott, H.M., Gascoyne, K.A., Gowda, R., Geary, I., Nicklin, M.J.H., Iannelli, F., 
Pozzi, G., Mitchell, T.J., Whyte, M.K.B., Sabroe, I., Dockrell, D.H. (2012) 
Interleukin-1 regulates CXCL8 release and influences disease outcome in 
response to streptococcus pneumoniae, defining intercellular cooperation 
between pulmonary epithelial cells and macrophages, Infection and Immunity, 80 
(3), pp. 1140-1149 
http://dx.doi.org/10.1128/IAI.05697-11  
 
 
IL-1β  regulates CXCL8 release and influences disease outcome in response to 1 
Streptococcus pneumoniae, defining intracellular cooperation between pulmonary epithelial 2 
cells and macrophages  3 
 4 
Helen M. Marriott1#, Kate A. Gascoyne1, 2#, Ravi Gowda2, Ian Geary1, Martin J.H. Nicklin1, 5 
Francesco Iannelli3, Gianni Pozzi3, Timothy J. Mitchell4, Moira K.B. Whyte1, 2, Ian Sabroe1, 2, 6 
and David H. Dockrell1, 2* 7 
 8 
1Department of Infection and Immunity, University of Sheffield Medical School and 2Sheffield 9 
Teaching Hospitals, UK, 3Laboratory of Molecular Microbiology and Biotechnology (LAMMB), 10 
Department of Biotechnology, University of Siena, Italy and 4 Institute of Infection, Immunity 11 
and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, 12 
UK University of Glasgow, UK 13 
 14 
#HMM and KAG contributed equally to this work 15 
 16 
*Corresponding Author:  David H. Dockrell 17 
Phone:  +44 (0) 114 226 1427 18 
Fax: +44 (0) 114 226 8898 19 
email: d.h.dockrell@sheffield.ac.uk 20 
 21 
Running title: Macrophage expressed IL-1β in pneumococcal pneumonia 22 
Word Count: Abstract:  24723 
 1
Abstract 24 
The success of Streptococcus pneumoniae (the pneumococcus) as a pulmonary pathogen is 25 
related to its restriction of innate immune responses by respiratory epithelial cells. The 26 
mechanisms used to overcome this restriction are incompletely elucidated. Pulmonary 27 
chemokine expression involves complex cellular and molecular networks, involving the 28 
pulmonary epithelium, but the specific cellular interactions and the cytokines that control them 29 
are incompletely defined. We show that serotype 2 or 4 pneumococci induce only modest levels 30 
of CXCL8 expression from epithelial cell lines, even in the absence of polysaccharide capsule. In 31 
contrast, co-culture of A549 cells with the macrophage-like THP-1 cell-line, differentiated with 32 
Vitamin D, or monocyte-derived macrophages, enhanced CXCL8 release. Supernatants from the 33 
THP-1 cell-line prime A549 cells to release CXCL8 at levels similar to co-cultures. IL-1Ra 34 
inhibits CXCL8 release from co-cultures and reduces the activity of macrophage-conditioned 35 
media, but inhibition of TNFα had only a minimal effect on CXCL8 release. Release of IL-1β 36 
but not TNFα was upregulated in co-cultures.  IL-1 type 1 receptor knockout C57BL/6 and 37 
BALB/c mice confirmed the importance of IL-1 signaling in CXC chemokine expression and 38 
neutrophil recruitment in vivo. In fulminant disease increased IL-1 signaling resulted in increased 39 
neutrophils in the airway and more invasive disease. These results demonstrate that IL-1 is an 40 
important component of the cellular network involving macrophages and epithelial cells, which 41 
facilitates CXC chemokine expression and aids neutrophil recruitment during pneumococcal 42 
pneumonia. They also highlight a potential clinical role for anti-IL-1 treatment to limit excessive 43 
neutrophilic inflammation in the lung.44 
 2
 Introduction 45 
Streptococcus pneumoniae (the pneumococcus) is a major cause of respiratory tract infection and 46 
invasive bacterial disease (6). S. pneumoniae is also a common commensal of the upper 47 
respiratory tract but innate host defences prevent disease in most colonized individuals (6, 40). 48 
The success of the innate response against pneumococcus is emphasized by the relatively low 49 
incidence of community-acquired pneumonia or invasive disease in comparison to the frequency 50 
of upper respiratory tract colonization (16, 39). 51 
 52 
The respiratory tract epithelium plays a critical role in the recognition of bacterial pathogens and 53 
in the induction of the inflammatory response (20). Epithelial cells express a range of Toll-like 54 
receptors (TLR) and other pattern recognition receptors (13). The clinical importance of these 55 
pathways of innate recognition of S. pneumoniae has been highlighted by the identification of 56 
genetic mutations or polymorphisms in these signaling pathways, which confer altered 57 
susceptibility to invasive pneumococcal disease (29, 31). Engagement of a range of pattern 58 
recognition receptors including TLRs, nucleotide-binding oligomerization domain (NOD) 59 
proteins and NOD-like receptor (NLR) family, pyrin domain containing 3 (NALP3) by 60 
pneumococci activates NF-κB and induces CXCL8 (IL-8) which leads to recruitment of 61 
polymorphonuclear leukocytes (neutrophils) (8, 25, 41, 49, 65). This is a key feature of 62 
pneumococcal infection when resident pulmonary defences are overwhelmed (15). 63 
 64 
Epithelial cell responses are enhanced by cooperative signaling with other cell types. 65 
Bronchoalveolar lavage fluid from lungs infected with pneumococci stimulates epithelial cell 66 
NF-κB activation (44), and alveolar macrophages enhance CXCL8 production by epithelial cells 67 
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in lung explants (66). It is postulated that, in order to avoid excessive inflammatory responses to 68 
commensal organisms, airway epithelial cells express constitutively low levels of TLRs, but 69 
studies of TLR2 expression indicate that it may be upregulated when inflammation is present 70 
(35, 64). Previous studies have demonstrated monocytes enhance epithelial cytokine responses to 71 
various TLR agonists (9, 37).  Increases in proinflammatory cytokine and chemokine release in 72 
co-cultures of pulmonary epithelial cells and monocytes have been noted in response to a range 73 
of lipopolysaccharides (9, 42, 52), staphylococcal exotoxins (30), Mycobacterium tuberculosis 74 
(63), and respiratory syncytial virus (RSV) (58). Thus, cell-cell communication between 75 
monocytes and epithelial cells is an important early step in the immune response to respiratory 76 
tract infections.  77 
 78 
 S. pneumoniae possess a number of virulence factors which may confound front-line immune 79 
responses (28), including a polysaccharide capsule which limits bacterial phagocytosis by 80 
macrophages (2) and inhibits bacterial attachment to respiratory epithelial cells (1, 22, 51).  In 81 
this study we have characterized the cellular and molecular factors involved in the regulation of 82 
CXCL8 expression by respiratory tract epithelial cells in response to S. pneumoniae infection. 83 
We demonstrate that IL-1β secretion by a macrophage-like cell-line is required for maximal 84 
secretion of CXCL8 by epithelial cells in response to S. pneumoniae in vitro. We also establish 85 
important roles for IL-1β in regulating the expression of CXC chemokines and rate IL-1 86 
signaling to the pulmonary infiltration of polymorphonuclear cells in vivo in murine models of S. 87 
pneumoniae infection.  88 
 89 
 90 
91 
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Materials and Methods 92 
Materials 93 
Gentamicin was purchased from Roussel laboratories (Uxbridge, UK); Vitamin D3 (1,25 94 
dihydroxy-cholecalciferol) from Sigma-Aldrich (Poole, UK); and recombinant human IL-1β, 95 
recombinant human soluble TNF Receptor Type 1, and recombinant human IL-1 receptor 96 
antagonist (IL-1Ra) from PeproTech EC Ltd (London, UK). 97 
 98 
Bacterial strains and growth conditions 99 
Streptococcus pneumoniae strains used in this study were serotype 2 strain D39 and its isogenic 100 
unencapsulated derivative FP22 (43) and serotype 4 strain TIGR4 and its unencapsulated 101 
derivative FP23 (2). D39 and TIGR4 were obtained from the American Type Culture Collection 102 
(ATCC) Bacteriology Collection, FP22 from Prof. Tim Mitchell (University of Glasgow), and 103 
FP23 from Prof. Gianni Pozzi and Dr Franco Ianelli (University of Sienna). Non typeable 104 
conjunctival clinical strains 08-1773 (MLST type 448) and 02-3522 (pre-MLST) were from Prof. 105 
Tim Mitchell and the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus 106 
Reference Laboratory (SHLMPRL).  Bacteria were grown to exponential phase in brain-heart 107 
infusion broth (Oxoid Unipath, Basingstoke, UK) with 20% heat-inactivated fetal calf serum 108 
(Autogen Bioclear, Wiltshire, UK) and aliquots were stored at -80°C. The concentration 109 
(CFU/ml) was determined by Miles Misra count for each strain as previously described (14). 110 
Freshly thawed aliquots were spun at 9,000 g for 2 min and the bacterial pellet washed twice in 111 
PBS prior to use. 112 
 113 
 114 
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Human cell culture 115 
All cell lines were obtained from the European Collection of Animal Cell Cultures (ECACC) and 116 
all culture media were from BioWhittaker (Lonza, Belgium). A549 cells, a human lung 117 
carcinoma cell line, were maintained in DMEM with 4.5g/l glucose, 2mmol/L L-glutamine, and 118 
10% fetal calf serum (FCS). Detroit 562 cells, a human pharyngeal carcinoma cell line, were 119 
maintained in EMEM with 2mmol/L L-glutamine and 10% FCS. Epithelial cells were seeded at 120 
2x105 cells/ml in 24-well plates (Costar) and grown to confluence for 24 h prior to use.  121 
THP-1 cells, a monocytic leukaemic cell line, were maintained in RPMI 1640 containing 122 
2mmol/L L-glutamine and 10% FCS. Differentiation to a macrophage phenotype was achieved 123 
by resuspending cells at 2x104 cells/ml in fresh media with the addition of Vitamin D3 (VD3) at 124 
10-7 M and incubation for 72 h in 5% CO2 at 37°C (26, 50).  This differentiation protocol 125 
produces a non-adherent immature macrophage phenotype more similar to an inflammatory 126 
macrophage than a highly differentiated tissue macrophage in terms of its response to microbial 127 
factors (12). Peripheral mononuclear cells were isolated from human blood as described 128 
previously (14), from healthy donors after informed consent and approval by the South Sheffield 129 
Research Ethics Committee. The following day after isolation non adherent cells were removed 130 
by washing in RPMI and adherent monocyte-derived macrophages (MDM) collected by gentle 131 
scraping.   Hemocytometer counts of all cell cultures were performed on the day of 132 
experimentation to determine approximate cell numbers per well. In co-cultures, non-adherent 133 
VD3-differentiated THP-1 or one day MDM were added to adherent A549 epithelial cells at a 134 
ratio of 1:10 (using data for cell numbers derived from the hemocytometer counts of 135 
representative wells of A549 cells) and cells were cultured in RPMI with 10% FCS (with low 136 
endotoxin levels). 137 
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 138 
Infection of cell cultures 139 
Growth medium was removed from epithelial cell monolayers and cells washed twice with PBS. 140 
Fresh growth medium (1ml per well) was applied and cells were infected with bacterial strains at 141 
an MOI of 10 for epithelial cells and 100 for VD3-differentiated THP-1 cells or MDM (to ensure 142 
the same number of bacteria were added to each well). Pneumococci were opsonized in RPMI 143 
1640 supplemented with 10% anti-pneumococcal immune serum and incubated on a rotating 144 
device for 30 min at 37 °C prior to infections for all experiments involving THP-1 cells and in 145 
experiments investigating the effect of opsonization on epithelial cell responses (2). Infected cell 146 
cultures were centrifuged at 150 g for 5 minutes prior to incubation at 37°C in 5% CO2. Culture 147 
medium (1ml) was removed from wells at each time point, spun at 10,000 g for 10 minutes and 148 
stored at -80°C prior to cytokine assay. Epithelial cells showed significant loss of viability 149 
following overnight incubation with S. pneumoniae and therefore gentamicin (100 μg/ml) was 150 
added to all wells at the 2 h time point to prevent bacterial overgrowth and loss of epithelial cell 151 
viability. As a positive control for CXCL8 production some wells were treated with 10ng/ml IL-152 
1β for the indicated time periods. 153 
 154 
Bacterial adherence assay 155 
Infected epithelial cell monolayers (MOI of 10) were centrifuged at 150 g for 5 min prior to 156 
incubation for 2 h at 37°C in 5% CO2. In certain experiments, specific variables were altered to 157 
determine their effect on adherence. These included increasing the MOI to 50; centrifuging at 158 
1,200 g; using opsonized pneumococci; and incubating for different durations. At 2 h (or at 1 h 159 
or 4 h in experiments with altered incubation periods) the medium (containing non-adherent 160 
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bacteria) was removed from each well and ‘non-adherent’ bacterial counts determined by Miles 161 
Misra (36). Epithelial cells (including any adherent bacteria) were then removed from each well 162 
with trypsin and versine and ‘adherent’ bacterial counts determined by Miles Misra. The 163 
proportion of adherent bacteria could then be calculated (62). 164 
 165 
Investigation of the nature of proinflammatory mediators generated in co-cultures 166 
To generate macrophage-conditioned media VD3-differentiated THP-1 cells (2x104/well) were 167 
exposed to opsonized D39 S. pneumoniae (MOI 100:1) or ‘mock infected’ (MCM-D or MCM-168 
MI) for 24 hours (gentamicin 100 μg/ml was added at 2 h to all wells). Macrophage conditioned 169 
media (MCM-D, MCM-MI) were removed from all wells at 24 h, spun at 10,000 g for 10 min 170 
and the supernatants (1 ml) then applied to epithelial cell monolayers. In blocking experiments, 171 
IL-1Ra (200 ng/ml) and/or soluble TNF receptor type 1 (sTNFR1; 50 ng/ml) were added to 172 
conditioned media after transfer onto epithelial cell monolayers at time zero. Plates were then 173 
incubated in 5% CO2 at 37°C and media removed from wells at 6 h, spun at 10,000 g for 10 174 
minutes, then stored at -80°C prior to cytokine assay. Samples of conditioned media were saved 175 
at time zero (following centrifugation) in order to determine baseline levels of CXCL8 prior to 176 
transfer onto epithelial monolayers. These baseline values were subtracted from the total CXCL8 177 
concentration at 6 h to calculate the amount produced by stimulated epithelial cells alone. 178 
 179 
Blockade of candidate proinflammatory molecules 180 
Co-culture wells were prepared as described above with A549 epithelial cells and THP-1 at a 181 
ratio of 10:1 and blocking agents (IL-1Ra, 200 ng/ml) (58, 63) and/or sTNFR1 (50 ng/ml) (38) 182 
were added at time zero.  Wells were then infected with opsonized pneumococci (MOI of 10), 183 
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spun at 150 g for 5 min, then incubated at 37°C in 5% CO2. Medium was removed at 6 h, spun at 184 
10,000 g for 10 min and stored at -80°C. Gentamicin (100 μg/ml) was added to all wells at 2 h. 185 
 186 
Role of soluble mediators 187 
To physically separate THP-1 and A549 cells, THP-1 were added to cell culture inserts, pore size 188 
1 µm (BD Falcon), with A549 cells in the well below, at ratio of 10:1 of A549:THP-1 cells. 189 
Opsonized D39 pneumococci were added at equal doses to both the insert and lower well 190 
compartments to achieve an overall MOI of 10:1 pneumococci: A549 cells. Plates were then 191 
spun at 150 g for 5 minutes, incubated at 37°C in 5% CO2, then media removed at 6 h, spun at 192 
10,000 g for 10 minutes and stored at -80°C. Gentamicin (100 μg/ml) was added to all wells at 2 193 
h. 194 
 195 
Murine pneumonia models 196 
IL-1 type 1 receptor knockout mice (18), allele Il1r1Tm1Imx, were kindly provided by Immunex 197 
Corporation to MJHN and were backcrossed for at least ten generations against both 198 
BALB/cOlaHsd and C57BL/6NHsd separately.  Heterozygotes were bred to yield homozygotes 199 
and working colonies of homozygotes were maintained. BALB/cOlaHsd or C57BL/6NHsd 200 
(Harlan) were used as wild-type controls.  Adult mice of both sexes were used.  All animal 201 
experiments were conducted in accordance with the Home Office Animals (Scientific 202 
Procedures) Act of 1986 and local ethical approval. 203 
Pulmonary infection of mice was with 5x105 or 1x107 CFU serotype 4 S. pneumoniae prepared 204 
and delivered by direct tracheal instillation as described previously (15).  24hrs post infection 205 
mice were killed by overdose of sodium pentobarbitone and bronchial alveolar fluid, lung and 206 
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blood collected for determination of cell differential, cytokines and viable bacteria in lung and 207 
blood as described previously (15). 208 
 209 
Cytokine assays 210 
CXCL8, IL-1β, and TNFα levels in the culture supernatants were measured using human 211 
CXCL8, IL-1β, and TNFα DuoSet ELISA kits respectively (R&D Systems, Abingdon, UK) 212 
according to manufacturer’s guidelines. Murine CXCL1, CXCL2 and TNFα were measured in 213 
BAL using murine CXCL1 and CXCL2 DuoSet ELISA kits (R&D Systems, Abingdon, UK) and 214 
murine TNFα ELISA Ready-SET-Go! reagent set (eBioscience, Hatfield, UK) respectively 215 
according to manufacturers’ guidelines.   216 
Optical densities were determined using Opsys MR microplate reader (Dynex Technologies). 217 
The lower limit of detection was approximately 30 pg/ml for CXCL8; 20 pg/ml for human IL-218 
1β; 30 pg/ml for human TNFα; 16 pg/ml for murine CXCL1; 32 pg/ml for murine CXCL and 16 219 
pg/ml for murine TNFα.  220 
 221 
Statistics  222 
All results are recorded as means +/- SEM unless otherwise stated. Statistical testing was 223 
performed using Prism 5.02 software (GraphPad software Inc.). Unpaired t test, Mann-Whitney 224 
or one-way ANOVA (with Bonferroni’s post-test) were used to analyse differences between 225 
groups, as appropriate. Significance was defined as p < 0.05. 226 
227 
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Results 228 
Epithelial cell responses to S. pneumoniae are limited by polysaccharide capsule. 229 
Epithelial cells contribute to innate host defense but S. pneumoniae contains several adaptations, 230 
which can modulate its interaction with epithelial cells (13, 19, 32, 59, 62), in particular the 231 
expression of polysaccharide capsule (1, 21, 22, 51, 57). The mechanisms used to integrate the 232 
epithelial cell response into the innate host response, despite microbiological restriction, are 233 
uncertain.  We confirmed that there was minimal adherence of encapsulated serotype 2 or 4 S. 234 
pneumoniae to epithelial cell lines (see supplemental data at 235 
http://www.shef.ac.uk/medicine/infectionandimmunity/staffprofiles/dockrell.html, Fig S1A-D). 236 
Binding was not significantly enhanced by opsonization of bacteria; by increasing the MOI to 237 
50:1; by increasing the incubation period; or by centrifuging the bacteria onto the cells at 1200 g 238 
rather than 150 g (data not shown). Mutants lacking capsule, either on a serotype 2 or 4 239 
background (2, 43), demonstrated significantly greater binding than the parental capsulated 240 
strains (see supplemental data at 241 
http://www.shef.ac.uk/medicine/infectionandimmunity/staffprofiles/dockrell.html, Fig S1A-D). 242 
CXCL8 is critical for the effective recruitment and activation of polymorphonuclear cells at 243 
sites of inflammation (3, 54). Microbial factors stimulate epithelial cells via a range of 244 
receptors to produce CXCL8 (5, 35, 49). We investigated the ability of non-opsonized 245 
pneumococci to stimulate CXCL8 release from epithelial cell monolayers. There was no 246 
significant difference between the CXCL8 response of mock-infected epithelial cells and those 247 
exposed to encapsulated pneumococci, which was low in comparison with cells stimulated with 248 
IL-1β (11) (Figure 1A-B). We demonstrated significantly greater CXCL8 production in 249 
response to unencapsulated pneumococci, however when we compared the encapsulated 250 
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serotype 2 and 4 strains to unencapsulated clinical strains we did not note any significant 251 
difference in CXCL8 release (see supplemental data at 252 
http://www.shef.ac.uk/medicine/infectionandimmunity/staffprofiles/dockrell.html, Fig S2), 253 
although it was not clear whether these results reflected the marked genetic differences between 254 
these unencapsulated strains and other pneumooccal serotypes. Opsonization modestly 255 
enhanced the epithelial cell CXCL8 response to encapsulated pneumococci (see supplemental 256 
data at http://www.shef.ac.uk/medicine/infectionandimmunity/staffprofiles/dockrell.html, Fig 257 
S3). We therefore opsonized pneumococci in all subsequent experiments. We also observed 258 
significantly greater CXCL8 responses to the unencapsulated serotype 4 strain, FP23, 259 
compared with other strains, possibly in keeping with enhanced pro-inflammatory cytokine 260 
responses to piliated pneumococci (4).  261 
 262 
Co-culture of epithelial cells with a macrophage-like cell-line enhances CXCL8 secretion 263 
following exposure to S. pneumoniae. 264 
Cytokine and chemokine responses can be enhanced in epithelial cell cultures by monocyte or 265 
macrophage derived factors (9, 30, 37, 42, 52, 53, 58, 63, 66). CXCL8 expression by the THP-266 
1 macrophage cell-line or epithelial cells in response to pneumococci was consistently less than 267 
the epithelial cell response to IL-1β (Figure 1C-D). In contrast, we demonstrated a marked 268 
enhancement of CXCL8 responses for macrophage-epithelial cell co-cultures. The generation 269 
of CXCL8 by co-cultures treated with pneumococci at 6 and 24 h time points was significantly 270 
greater than the sum of the CXCL8 responses of A549 epithelial cells and THP-1 cells alone. 271 
The responses were apparent by 6 h after infection and were sustained up to 24 h after 272 
infection. We therefore used the 6 h time point in subsequent experiments. Similar results were 273 
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obtained with the Detroit epithelial cell line, which also showed enhanced CXCL8 expression 274 
in co-culture conditions (data not shown). Interestingly, although the macrophage-like cell line 275 
showed a significantly greater CXCL8 response to encapsulated compared with unencapsulated 276 
bacteria, the presence of polysaccharide capsule had little effect on the magnitude of the co-277 
culture response to pneumococci. We also noted that opsonization corrected the inhibitory 278 
effect of capsule on the response of epithelial cell monocultures to pneumococci.  279 
 280 
IL-1 production by the THP-1 macrophage-like cell-line stimulates CXCL8 expression from 281 
epithelial cells following exposure to S. pneumoniae. 282 
We next addressed whether cell contact between THP-1 cells and epithelial cells was a 283 
necessary or contributory factor. When epithelial cells were separated from monocytes using 284 
semi-permeable transwells we observed no significant reduction in CXCL8 secretion (Figure 285 
2), suggesting that direct cell contact was not required and that a soluble factor was responsible 286 
for priming the epithelial cells. Bronchial alveolar fluid from the lungs of mice infected with S. 287 
pneumoniae has been shown to stimulate NF-κB activation and resultant chemokine expression 288 
by epithelial cells although the cellular source of the factors responsible are incompletely 289 
characterized (44). Previous work from our group has indicated in a number of models that IL-290 
1 may play important roles in the induction of inflammatory responses (9, 38). When we 291 
transferred supernatants from the mock-infected THP-1 cells onto epithelial monolayers, we 292 
observed little release of CXCL8, while supernatants from the S. pneumoniae-exposed THP-1 293 
cells induced levels of CXCL8 secretion comparable to infected co-cultures (Figure 3). We also 294 
investigated the mediators responsible for activation of A549 cells by bacterial-exposed THP-1 295 
cells, and focused on the two dominant ‘early’ proinflammatory cytokines, TNFα and IL-1  296 
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(24, 27, 45, 52). IL-1Ra, but not soluble TNFα Receptor 1, treatment blocked the ability of 297 
macrophage conditioned media to stimulate CXCL8 production by the epithelial cell line.  298 
 299 
IL-1Ra inhibits CXCL8 release from co-cultures challenged S. pneumoniae. 300 
We next addressed whether the contribution of IL-1 and TNFα altered with bacterial strain. IL-301 
1Ra reduced CXCL8 secretion by co-cultures in the presence of both encapsulated and 302 
unencapsulated strains and also the piliated type 4 strains (4).  TNFα blockade had no effect on 303 
CXCL8 secretion in the presence or absence of IL-1Ra at the 6 h time point (Figure 4) and 304 
made only a minor contribution to CXCL8 release in co-cultures at 24 h, which only reached 305 
statistical significance for the unencapsulated type 4 pneumococci (see supplemental data at 306 
http://www.shef.ac.uk/medicine/infectionandimmunity/staffprofiles/dockrell.html, Fig S4). 307 
Overall these findings suggested that IL-1 was the major factor enhancing CXCL8 release. We 308 
also confirmed that if we used primary monocyte-derived macrophages (MDM) one day after 309 
differentiation from monocytes they were also able to enhance CXCL8 production from 310 
epithelial cells and that IL-1 also contributed to this release (Figure 5). 311 
 312 
IL-1β release is enhanced in co-cultures. 313 
We next confirmed IL-1β and TNFα release from the THP-1 cell line following challenge with 314 
D39 pneumococci, excluding the possibility that the lack of inhibition by TNFα blockade was 315 
merely a consequence of lack of production (Figure 6A-B). However, only IL-1β was enhanced 316 
in co-cultures. The same pattern of cytokine release was observed in response to type 4 317 
pneumococci (data not shown). We also showed that neither IL-1β nor TNFα were induced 318 
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following application of macrophage-conditioned media to epithelial cell monolayers, thus 319 
confirming the THP-1 cells as the major source of IL-1β and TNFα  (Figure 6C-D).  320 
 321 
Modulation of IL-1 signaling alters production of CXC chemokines and polymorphonuclear 322 
cell recruitment during S. pneumoniae infection in vivo. 323 
To confirm the relevance of these findings we next investigated pneumonia models in mice 324 
with differing sensitivity to IL-1 signaling (23). C57BL/6 mice recruit polymorphonuclear cells 325 
only when resident host defenses against pneumococci become overwhelmed (17).  BALB/c 326 
mice develop an early neutrophilic response against pneumococci, which is greater than that 327 
seen in C57BL/6 mice. Il1r1-/- C57BL/6 mice have normal leukocyte numbers but a reduction 328 
in early bacterial clearance in a model of pneumococcal pneumonia (18, 46), while Il1r1-/- 329 
BALB/c mice have never been studied in a model of pneumococcal pneumonia to our 330 
knowledge. We confirmed that polymorphonuclear cell recruitment was greater for BALB/c 331 
mice than for C57BL/6 mice following challenge with a similar dose of pneumococci (Figure 332 
7A and D). In each genetic background Il1r1-/- mice recruited fewer polymorphonuclear cells. 333 
 334 
We then addressed the expression of CXCL1 (KC) and CXCL2 (MIP-2α), which are the 335 
murine paralogs of CXCL8 in each mouse strain. CXCL1 was significantly reduced in each 336 
Il1r1-/- mouse strain (Figure 7B and E).  There was a non-significant decrease in CXCL2 for 337 
Il1r1-/- C57BL/6 and no alteration in Il1r1-/- BALB/c mice (Figure 7C and F). Although 338 
numbers of mice were small the Il1r1-/- C57BL/6 had a trend towards increased bacterial 339 
numbers in lung and blood, in keeping with prior observations (46),  but there was no 340 
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difference in bacterial numbers in Il1r1-/- BALB/c mice (see supplemental data at 341 
http://www.shef.ac.uk/medicine/infectionandimmunity/staffprofiles/dockrell.html, Fig S5). 342 
 343 
Modulation of IL-1 signaling can reduce the severity of invasive disease in fulminant 344 
pneumococcal infection. 345 
We next increased the severity of infection in the BALB/c mice, which increased the number of 346 
polymorphonuclear cells in the BAL. In this model polymorphonuclear cells recruitment was 347 
again reduced in the Il1r1-/- mice (Figure 8A), although levels of recruitment were much greater 348 
than with the lower dose infection model (compare with Figure 7D). Interestingly CXCL1/2 349 
expression was not lower in the lungs of Il1r1-/- mice with severe disease (Figure 8B-C).  This 350 
suggested other compensatory changes in the cytokine network might have occurred to enable 351 
neutrophil recruitment and we observed that levels of TNFα, a known stimulus for CXCL1 352 
chemokine expression during pneumococcal infection (55), was increased in Il1r1-/-  BALB/c 353 
mice (Figure 8D).  We found no alteration in colony counts in the lung but a significant 354 
decrease in colony counts in the blood of Il1r1-/- BALB/c mice (Figure 8E-F).  355 
356 
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Discussion 357 
In this study, we demonstrate a major role for macrophage-alveolar epithelial cell signaling 358 
during the initial phase of host defence against S. pneumoniae. We describe a critical role for IL-359 
1 in stimulating CXCL8 release in response to S. pneumoniae and show that a macrophage cell-360 
line and primary macrophages are an important source of this cytokine. In vivo models have 361 
confirmed that IL-1 signaling stimulates CXCL1/2 chemokine expression in mice and facilitates 362 
recruitment of polymorphonuclear leukocytes to the lung during infection.  363 
  364 
Respiratory epithelial cells are an important component of pulmonary host defense, possessing 365 
pattern recognition receptors, such as TLRs, which enable sensing of micro-organisms and link 366 
recognition of bacteria to NF-κΒ activation and transcription of cytokines and chemokines (13, 367 
20, 44). Hyporesponsiveness in this system, as recently demonstrated for an association between 368 
IRAK4 polymorphisms and susceptibility to Gram-positive infections in patients with critical 369 
illness, limit the effectiveness of the innate immune responses (56). We show that direct 370 
exposure of A549 cells to pneumococci induces only low level CXCL8 secretion. Capsule limits 371 
the adherence of pneumococci to epithelial cells (21, 51) and this was confirmed again in our 372 
study. Nevertheless cytokine expression correlates poorly with adherence; previous studies have 373 
found that the epithelial cell inflammatory response is not associated with the level of bacterial 374 
adherence (7), nor is it associated with the binding capacity of particular pneumococcal strains 375 
(48). Some bacteria can adhere and invade epithelial cell surfaces by downregulation of capsule, 376 
while some encapsulated strains can coat themselves in IgA fragments to overcome the 377 
electrostatic effects of a negatively charged capsule (21, 62).  378 
 379 
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Epithelial cell responses during inflammation are, however, dependent on a cellular network in 380 
which additional cell types prime epithelial cells to upregulate chemokine release (37, 42). These 381 
networks contain multiple potential cellular sources of a broad range of cytokines, including 382 
monocyte synthesis and secretion of IL-1β and TNFα, which can prime alveolar epithelial cells 383 
to release CXCL8 (37, 42, 53). In the context of the early stages of pneumococcal infection, both 384 
IL-1β and TNFα are important in stimulating NF-κB activation in pulmonary epithelium (44) 385 
but the sources of these cytokines are not fully defined. There is evidence that macrophages 386 
enhance CXCL8 expression in lung explants, but which cell types produce the cytokine is 387 
uncertain (66). We now show that a macrophage phenotype, resembling monocytes or 388 
inflammatory macrophages (12), releases IL-1 to stimulate CXCL8 release from  a type II 389 
alveolar epithelial cell-line. In contrast macrophage-expressed TNFα was not a significant factor 390 
in priming epithelial cells to produce CXCL8 in co-cultures containing the macrophage cell line.  391 
The response induced by primary macrophages also involved IL-1 but the degree of inhibition by 392 
IL-1Ra was less marked suggesting other factors could also play a role.  393 
 394 
These findings are consistent with data from previous studies which observed that IL-1Ra inhibits 395 
epithelial cell CXCL8 secretion in response to conditioned media from M. tuberculosis-infected human 396 
monocytes (63) and in response to conditioned media from RSV-infected monocytes (58).  Teichoic 397 
acid in the pneumococcal cell wall is a potent stimulus for IL-1 expression from monocytes (45). 398 
Teichoicated species in the cell wall could be the predominant microbial factor driving the enhanced 399 
CXCL8 response in co-cultures, with an additional role played by strain variable factors such as pili, a 400 
known stimulus for TNFα production, at later stages of infection or during the fulminant mouse model 401 
when IL-1 signaling was impaired.  402 
 18
In interpreting the results of our study it is necessary to bear in mind the complex nature of cell-cell 403 
signaling and cytokine networks. It is possible that the synergistic response in co-culture conditions 404 
involves a component of bidirectional signaling between macrophages and epithelial cells (60). 405 
Although macrophage conditioned media enhanced CXCL8 secretion from epithelial cells, signals 406 
could flow in the reverse direction. IL-1β expression was enhanced in co-cultures. Activating signals 407 
from stimulated epithelial cells may potentiate the response of monocytes or macrophages (and 408 
possibly other immune cells in vivo), with inflammatory mediators acting in a paracrine fashion to 409 
stimulate production of other effector molecules. Once the initial recruitment of polymorphonuclear 410 
leukocytes has occurred these cells can release IL-1β to fuel further chemokine release from 411 
macrophages and non-myeloid cells, as demonstrated recently in a murine model of arthritis (10). 412 
 413 
Co-cultures of A549 and THP-1 cell-lines provide a useful and well-recognized in vitro model of the 414 
alveolar space. We can confirm that the VD3-differentiated THP-1 cells have a differentiation state 415 
which resembles a monocyte or macrophage in the early stage of tissue differentiation (12). We 416 
verified findings with a primary macrophage that was also in the early stage of differentiation. Our 417 
confirmation in vivo using two different strains of mice, that modulation of IL-1 signaling influences 418 
CXCL1/2 expression and polymorphonuclear cell numbers in the lung during pneumococcal 419 
pneumonia confirmed in vivo the validity of this approach. Other studies have supported our findings 420 
that IL-1 contributes to host defense in vivo against pneumococci, although in the case of the lung the 421 
effects were most important in the first 24-48 h after infection (45, 67).  422 
  423 
IL-1 dependent neutrophilic inflammation has improved bacterial clearance in a previous model of 424 
pneumococcal pneumonia (46), and our studies with moderate bacterial inocula were consistent with 425 
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this. However, in fulminant disease, neutrophilic inflammation and reactive oxygen species generation 426 
by polymorphonuclear leukocytes may adversely affect clinical outcomes (33, 34) and we observed 427 
that IL-1 dependent neutrophilic inflammation enhanced levels of tissue invasion and bacteremia. In 428 
some settings neutrophil depletion can improve outcomes in murine models of fulminant pneumonia 429 
(33). We have previously highlighted the potential importance of leukocyte-derived IL-1 in the 430 
initiation of airways inflammation (37, 38, 42). The data shown here provide further support for the 431 
concept that targeting IL-1 in airways infection may in some settings be able to limit damaging effects 432 
of excessive inflammation by suppressing signaling between monocytes/macrophages and airway 433 
epithelial cells. This may be more tractable than manipulation of other pathways such as the TNFα 434 
pathway which may have more significant overall effects in regulating host responses to pneumococci 435 
(46). Alternatively, since TNFα was raised in the absence of IL-1 signaling in the Il1r1-/- mice, it might 436 
be that the combined inhibition of IL-1 and TNFα signaling would be more effective at inhibiting 437 
CXC chemokine generation. Any potential benefits would need to be weighed carefully against the 438 
possible harmful effects of inhibiting recruitment of the minimum number of polymorphonuclear 439 
leukocytes required to clear micro-organisms. The timing of administration is likely to be key. 440 
Administration would need to be delayed until after the early stages of the host response and would 441 
ideally involve identifying a sub-group of patients with selective markers indicating that an excessive 442 
inflammatory response might develop and predispose the individual to complications such as acute 443 
respiratory distress syndrome (ARDS), which may occur following pneumonia (61). Previous studies 444 
using IL-1Ra in the early stages of pneumonia evolution have not shown substantial alteration in 445 
inflammatory outcomes or survival in a murine model (47), but targeting such an intervention to select 446 
patients with markers of more severe inflammation might be tractable. 447 
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In conclusion, we present evidence for a synergistic relationship between alveolar epithelial cells and 448 
macrophages in the early inflammatory response to S. pneumoniae. We demonstrate a critical role for 449 
IL-1 signaling in CXC chemokine expression and neutrophil recruitment to the murine lung during 450 
pneumococcal pneumonia and suggest that in fulminant disease therapeutic modulation of this 451 
pathway, as could be achieved with IL-1Ra could reduce the extent of invasive disease.  452 
453 
 21
Acknowledgments: 454 
The authors’ work is supported by a Wellcome Trust Senior Clinical Fellowship to DHD 455 
(#076945), a British Lung Foundation Fellowship (F05/7) and a MRC Discipline Hopping Grant 456 
(G0902354) to HMM and by grants from Wellcome Trust and Medical Research Council to 457 
TJM. IS and MKBW are supported by a MRC Research Grant (G0801983). 458 
459 
 22
References 460 
1. Adamou, J. E., T. M. Wizemann, P. Barren, and S. Langermann. 1998. Adherence of 461 
Streptococcus pneumoniae to human bronchial epithelial cells (BEAS-2B). Infection and 462 
Immunity 66:820-822. 463 
2. Ali, F., M. E. Lee, F. Iannelli, G. Pozzi, T. J. Mitchell, R. C. Read, and D. H. 464 
Dockrell. 2003. Streptococcus pneumoniae-associated human macrophage apoptosis 465 
after bacterial internalization via complement and Fcgamma receptors correlates with 466 
intracellular bacterial load. Journal of Infectious Diseases 188:1119-1131. 467 
3. Baggiolini, M., A. Walz, and S. L. Kunkel. 1989. Neutrophil-activating peptide-468 
1/interleukin 8, a novel cytokine that activates neutrophils. Journal of Clinical 469 
Investigation 84:1045-1049. 470 
4. Barocchi, M. A., J. Ries, X. Zogaj, C. Hemsley, B. Albiger, A. Kanth, S. Dahlberg, J. 471 
Fernebro, M. Moschioni, V. Masignani, K. Hultenby, A. R. Taddei, K. Beiter, F. 472 
Wartha, A. von Euler, A. Covacci, D. W. Holden, S. Normark, R. Rappuoli, and B. 473 
Henriques-Normark. 2006. A pneumococcal pilus influences virulence and host 474 
inflammatory responses. Proceedings of the National Academy of Sciences of the United 475 
States of America 103:2857-2862. 476 
5. Beisswenger, C., E. S. Lysenko, and J. N. Weiser. 2009. Early bacterial colonization 477 
induces toll-like receptor-dependent transforming growth factor beta signaling in the 478 
epithelium. Infection and Immunity 77:2212-2220. 479 
6. Bogaert, D., R. De Groot, and P. W. Hermans. 2004. Streptococcus pneumoniae 480 
colonisation: the key to pneumococcal disease. Lancet Infectious Diseases 4:144-154. 481 
 23
7. Bootsma, H. J., M. Egmont-Petersen, and P. W. Hermans. 2007. Analysis of the in 482 
vitro transcriptional response of human pharyngeal epithelial cells to adherent 483 
Streptococcus pneumoniae: evidence for a distinct response to encapsulated strains. 484 
Infection and Immunity 75:5489-5499. 485 
8. Calbo, E., and J. Garau. 2010. Of mice and men: innate immunity in pneumococcal 486 
pneumonia. International Journal of Antimicrobial Agents 35:107-113. 487 
9. Chaudhuri, N., C. Paiva, K. Donaldson, R. Duffin, L. C. Parker, and I. Sabroe. 488 
Diesel exhaust particles override natural injury-limiting pathways in the lung. Am J 489 
Physiol Lung Cell Mol Physiol 299:L263-271. 490 
10. Chou, R. C., N. D. Kim, C. D. Sadik, E. Seung, Y. Lan, M. H. Byrne, B. Haribabu, 491 
Y. Iwakura, and A. D. Luster. 2010. Lipid-cytokine-chemokine cascade drives 492 
neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 33:266-493 
278. 494 
11. Coulter, K. R., M. D. Wewers, M. P. Lowe, and D. L. Knoell. 1999. Extracellular 495 
regulation of interleukin (IL)-1beta through lung epithelial cells and defective IL-1 type 496 
II receptor expression. American Journal of Respiratory Cell and Molecular Biology 497 
20:964-975. 498 
12. Daigneault, M., J. A. Preston, H. M. Marriott, M. K. Whyte, and D. H. Dockrell. 499 
2010. The identification of markers of macrophage differentiation in PMA-stimulated 500 
THP-1 cells and monocyte-derived macrophages. PLoS One 5:e8668. 501 
13. Diamond, G., D. Legarda, and L. K. Ryan. 2000. The innate immune response of the 502 
respiratory epithelium. Immunological Reviews 173:27-38. 503 
 24
14. Dockrell, D. H., M. Lee, D. H. Lynch, and R. C. Read. 2001. Immune-mediated 504 
phagocytosis and killing of Streptococcus pneumoniae are associated with direct and 505 
bystander macrophage apoptosis. J Infect Dis 184:713-722. 506 
15. Dockrell, D. H., H. M. Marriott, L. R. Prince, V. C. Ridger, P. G. Ince, P. G. 507 
Hellewell, and M. K. Whyte. 2003. Alveolar macrophage apoptosis contributes to 508 
pneumococcal clearance in a resolving model of pulmonary infection. J Immunol 509 
171:5380-5388. 510 
16. Eskola, J., A. K. Takala, E. Kela, E. Pekkanen, R. Kalliokoski, and M. Leinonen. 511 
1992. Epidemiology of invasive pneumococcal infections in children in Finland. Journal 512 
of the American Medical Association 268:3323-3327. 513 
17. Gingles, N. A., J. E. Alexander, A. Kadioglu, P. W. Andrew, A. Kerr, T. J. Mitchell, 514 
E. Hopes, P. Denny, S. Brown, H. B. Jones, S. Little, G. C. Booth, and W. L. 515 
McPheat. 2001. Role of genetic resistance in invasive pneumococcal infection: 516 
identification and study of susceptibility and resistance in inbred mouse strains. Infect 517 
Immun 69:426-434. 518 
18. Glaccum, M. B., K. L. Stocking, K. Charrier, J. L. Smith, C. R. Willis, C. 519 
Maliszewski, D. J. Livingston, J. J. Peschon, and P. J. Morrissey. 1997. Phenotypic 520 
and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 521 
159:3364-3371. 522 
19. Gosink, K. K., E. R. Mann, C. Guglielmo, E. I. Tuomanen, and H. R. Masure. 2000. 523 
Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. 524 
Infection and Immunity 68:5690-5695. 525 
 25
20. Gribar, S. C., W. M. Richardson, C. P. Sodhi, and D. J. Hackam. 2008. No Longer an 526 
Innocent Bystander: Epithelial Toll-Like Receptor Signaling in the Development of 527 
Mucosal Inflammation. Molecular Medicine 14:645-659. 528 
21. Hammerschmidt, S., S. Wolff, A. Hocke, S. Rosseau, E. Muller, and M. Rohde. 2005. 529 
Illustration of pneumococcal polysaccharide capsule during adherence and invasion of 530 
epithelial cells. Infect Immun 73:4653-4667. 531 
22. Hathaway, L. J., P. Battig, and K. Muhlemann. 2007. In vitro expression of the first 532 
capsule gene of Streptococcus pneumoniae, cpsA, is associated with serotype-specific 533 
colonization prevalence and invasiveness. Microbiology 153:2465-2471. 534 
23. Herbold, W., R. Maus, I. Hahn, N. Ding, M. Srivastava, J. W. Christman, M. Mack, 535 
J. Reutershan, D. E. Briles, J. C. Paton, C. Winter, T. Welte, and U. A. Maus. 536 
Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage 537 
recruitment in response to pneumococcal lung infection. Infect Immun 78:2620-2630. 538 
24. Heumann, D., C. Barras, A. Severin, M. P. Glauser, and A. Tomasz. 1994. Gram-539 
positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by 540 
human monocytes. Infection and Immunity 62:2715-2721. 541 
25. Hippenstiel, S., B. Opitz, B. Schmeck, and N. Suttorp. 2006. Lung epithelium as a 542 
sentinel and effector system in pneumonia--molecular mechanisms of pathogen 543 
recognition and signal transduction. Respiratory Research 7:97. 544 
26. Hmama, Z., D. Nandan, L. Sly, K. L. Knutson, P. Herrera-Velit, and N. E. Reiner. 545 
1999. 1alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated 546 
by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. Journal of 547 
Experimental Medicine 190:1583-1594. 548 
 26
27. Jones, M. R., B. T. Simms, M. M. Lupa, M. S. Kogan, and J. P. Mizgerd. 2005. Lung 549 
NF-kappaB activation and neutrophil recruitment require IL-1 and TNF receptor 550 
signaling during pneumococcal pneumonia. Journal of Immunology 175:7530-7535. 551 
28. Kadioglu, A., J. N. Weiser, J. C. Paton, and P. W. Andrew. 2008. The role of 552 
Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. 553 
Nature Reviews. Microbiology 6:288-301. 554 
29. Khor, C. C., S. J. Chapman, F. O. Vannberg, A. Dunne, C. Murphy, E. Y. Ling, A. 555 
J. Frodsham, A. J. Walley, O. Kyrieleis, A. Khan, C. Aucan, S. Segal, C. E. Moore, 556 
K. Knox, S. J. Campbell, C. Lienhardt, A. Scott, P. Aaby, O. Y. Sow, R. T. Grignani, 557 
J. Sillah, G. Sirugo, N. Peshu, T. N. Williams, K. Maitland, R. J. Davies, D. P. 558 
Kwiatkowski, N. P. Day, D. Yala, D. W. Crook, K. Marsh, J. A. Berkley, L. A. 559 
O'Neill, and A. V. Hill. 2007. A Mal functional variant is associated with protection 560 
against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature 561 
Genetics 39:523-528. 562 
30. Krakauer, T. 2002. Stimulant-dependent modulation of cytokines and chemokines by 563 
airway epithelial cells: cross talk between pulmonary epithelial and peripheral blood 564 
mononuclear cells. Clinical and Diagnostic Laboratory Immunology 9:126-131. 565 
31. Ku, C. L., H. von Bernuth, C. Picard, S. Y. Zhang, H. H. Chang, K. Yang, M. 566 
Chrabieh, A. C. Issekutz, C. K. Cunningham, J. Gallin, S. M. Holland, C. Roifman, 567 
S. Ehl, J. Smart, M. Tang, F. J. Barrat, O. Levy, D. McDonald, N. K. Day-Good, R. 568 
Miller, H. Takada, T. Hara, S. Al-Hajjar, A. Al-Ghonaium, D. Speert, D. Sanlaville, 569 
X. Li, F. Geissmann, E. Vivier, L. Marodi, B. Z. Garty, H. Chapel, C. Rodriguez-570 
Gallego, X. Bossuyt, L. Abel, A. Puel, and J. L. Casanova. 2007. Selective 571 
 27
predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent 572 
TLRs are otherwise redundant in protective immunity. Journal of Experimental Medicine 573 
204:2407-2422. 574 
32. Magee, A. D., and J. Yother. 2001. Requirement for capsule in colonization by 575 
Streptococcus pneumoniae. Infection and Immunity 69:3755-3761. 576 
33. Marks, M., T. Burns, M. Abadi, B. Seyoum, J. Thornton, E. Tuomanen, and L. A. 577 
Pirofski. 2007. Influence of neutropenia on the course of serotype 8 pneumococcal 578 
pneumonia in mice. Infect Immun 75:1586-1597. 579 
34. Marriott, H. M., L. E. Jackson, T. S. Wilkinson, A. J. Simpson, T. J. Mitchell, D. J. 580 
Buttle, S. S. Cross, P. G. Ince, P. G. Hellewell, M. K. Whyte, and D. H. Dockrell. 581 
2008. Reactive oxygen species regulate neutrophil recruitment and survival in 582 
pneumococcal pneumonia. Am J Respir Crit Care Med 177:887-895. 583 
35. Mayer, A. K., M. Muehmer, J. Mages, K. Gueinzius, C. Hess, K. Heeg, R. Bals, R. 584 
Lang, and A. H. Dalpke. 2007. Differential recognition of TLR-dependent microbial 585 
ligands in human bronchial epithelial cells. Journal of Immunology 178:3134-3142. 586 
36. Miles, A. A., S. S. Misra, and J. O. Irwin. 1938. The estimation of the bactericidal 587 
power of the blood. Journal of Hygiene 38:732-749. 588 
37. Morris, G. E., L. C. Parker, J. R. Ward, E. C. Jones, M. K. Whyte, C. E. Brightling, 589 
P. Bradding, S. K. Dower, and I. Sabroe. 2006. Cooperative molecular and cellular 590 
networks regulate Toll-like receptor-dependent inflammatory responses. FASEB J 591 
20:2153-2155. 592 
38. Morris, G. E., M. K. Whyte, G. F. Martin, P. J. Jose, S. K. Dower, and I. Sabroe. 593 
2005. Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via 594 
 28
mononuclear leukocytes. American Journal of Respiratory and Critical Care Medicine 595 
171:814-822. 596 
39. Musher, D. M. 1992. Infections caused by Streptococcus pneumoniae: clinical spectrum, 597 
pathogenesis, immunity, and treatment. Clinical Infectious Diseases 14:801-807. 598 
40. Obaro, S., and R. Adegbola. 2002. The pneumococcus: carriage, disease and conjugate 599 
vaccines. Journal of Medical Microbiology 51:98-104. 600 
41. Opitz, B., A. Puschel, B. Schmeck, A. C. Hocke, S. Rosseau, S. Hammerschmidt, R. 601 
R. Schumann, N. Suttorp, and S. Hippenstiel. 2004. Nucleotide-binding 602 
oligomerization domain proteins are innate immune receptors for internalized 603 
Streptococcus pneumoniae. Journal of Biological Chemistry 279:36426-36432. 604 
42. Parker, L. C., E. C. Prestwich, J. R. Ward, E. Smythe, A. Berry, M. Triantafilou, K. 605 
Triantafilou, and I. Sabroe. 2008. A phosphatidylserine species inhibits a range of 606 
TLR- but not IL-1beta-induced inflammatory responses by disruption of membrane 607 
microdomains. J Immunol 181:5606-5617. 608 
43. Pearce, B. J., F. Iannelli, and G. Pozzi. 2002. Construction of new unencapsulated 609 
(rough) strains of Streptococcus pneumoniae. Research in Microbiology 153:243-247. 610 
44. Quinton, L. J., M. R. Jones, B. T. Simms, M. S. Kogan, B. E. Robson, S. J. Skerrett, 611 
and J. P. Mizgerd. 2007. Functions and regulation of NF-kappaB RelA during 612 
pneumococcal pneumonia. Journal of Immunology 178:1896-1903. 613 
45. Riesenfeld-Orn, I., S. Wolpe, J. F. Garcia-Bustos, M. K. Hoffmann, and E. 614 
Tuomanen. 1989. Production of interleukin-1 but not tumor necrosis factor by human 615 
monocytes stimulated with pneumococcal cell surface components. Infection and 616 
Immunity 57:1890-1893. 617 
 29
46. Rijneveld, A. W., S. Florquin, J. Branger, P. Speelman, S. J. Van Deventer, and T. 618 
van der Poll. 2001. TNF-alpha compensates for the impaired host defense of IL-1 type I 619 
receptor-deficient mice during pneumococcal pneumonia. J Immunol 167:5240-5246. 620 
47. Rijneveld, A. W., S. Florquin, P. Speelman, C. K. Edwards, C. A. Dinarello, and T. 621 
van der Poll. 2003. Interleukin-1 receptor antagonist transiently impairs antibacterial 622 
defense but not survival in murine pneumococcal pneumonia. Eur Cytokine Netw 623 
14:242-245. 624 
48. Robson, R. L., N. A. Reed, and R. T. Horvat. 2006. Differential activation of 625 
inflammatory pathways in A549 type II pneumocytes by Streptococcus pneumoniae 626 
strains with different adherence properties. BMC Infectious Diseases 6:71. 627 
49. Schmeck, B., S. Huber, K. Moog, J. Zahlten, A. C. Hocke, B. Opitz, S. 628 
Hammerschmidt, T. J. Mitchell, M. Kracht, S. Rosseau, N. Suttorp, and S. 629 
Hippenstiel. 2006. Pneumococci induced TLR- and Rac1-dependent NF-kappaB-630 
recruitment to the IL-8 promoter in lung epithelial cells. American journal of physiology. 631 
Lung cellular and molecular physiology 290:L730-L737. 632 
50. Schwende, H., E. Fitzke, P. Ambs, and P. Dieter. 1996. Differences in the state of 633 
differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. 634 
Journal of Leukocyte Biology 59:555-561. 635 
51. Selinger, D. S., and W. P. Reed. 1979. Pneumococcal adherence to human epithelial 636 
cells. Infection and Immunity 23:545-548. 637 
52. Standiford, T. J., S. L. Kunkel, M. A. Basha, S. W. Chensue, J. P. Lynch, 3rd, G. B. 638 
Toews, J. Westwick, and R. M. Strieter. 1990. Interleukin-8 gene expression by a 639 
 30
pulmonary epithelial cell line. A model for cytokine networks in the lung. Journal of 640 
Clinical Investigation 86:1945-1953. 641 
53. Standiford, T. J., S. L. Kunkel, S. H. Phan, B. J. Rollins, and R. M. Strieter. 1991. 642 
Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 643 
expression from human pulmonary type II-like epithelial cells. Journal of Biological 644 
Chemistry 266:9912-9918. 645 
54. Strieter, R. M., S. L. Kunkel, M. P. Keane, and T. J. Standiford. 1999. Chemokines 646 
in lung injury: Thomas A. Neff Lecture. Chest 116:103S-110S. 647 
55. Sun, K., S. L. Salmon, S. A. Lotz, and D. W. Metzger. 2007. Interleukin-12 promotes 648 
gamma interferon-dependent neutrophil recruitment in the lung and improves protection 649 
against respiratory Streptococcus pneumoniae infection. Infect Immun 75:1196-1202. 650 
56. Sutherland, A. M., K. R. Walley, T. A. Nakada, A. H. Sham, M. M. Wurfel, and J. 651 
A. Russell. A nonsynonymous polymorphism of IRAK4 associated with increased 652 
prevalence of gram-positive infection and decreased response to toll-like receptor 653 
ligands. J Innate Immun 3:447-458. 654 
57. Talbot, U. M., A. W. Paton, and J. C. Paton. 1996. Uptake of Streptococcus 655 
pneumoniae by respiratory epithelial cells. Infection and Immunity 64:3772-3777. 656 
58. Thomas, L. H., M. I. Wickremasinghe, M. Sharland, and J. S. Friedland. 2000. 657 
Synergistic upregulation of interleukin-8 secretion from pulmonary epithelial cells by 658 
direct and monocyte-dependent effects of respiratory syncytial virus infection. Journal of 659 
Virology 74:8425-8433. 660 
59. Tong, H. H., L. E. Blue, M. A. James, and T. F. DeMaria. 2000. Evaluation of the 661 
virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in 662 
 31
nasopharyngeal colonization and development of otitis media in the chinchilla model. 663 
Infection and Immunity 68:921-924. 664 
60. Ward, J. R., S. E. Francis, L. Marsden, T. Suddason, G. M. Lord, S. K. Dower, D. 665 
C. Crossman, and I. Sabroe. 2009. A central role for monocytes in Toll-like receptor-666 
mediated activation of the vasculature. Immunology 128:58-68. 667 
61. Ware, L. B., and M. A. Matthay. 2000. The acute respiratory distress syndrome. The 668 
New England journal of medicine 342:1334-1349. 669 
62. Weiser, J. N., D. Bae, C. Fasching, R. W. Scamurra, A. J. Ratner, and E. N. Janoff. 670 
2003. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proceedings 671 
of the National Academy of Sciences of the United States of America 100:4215-4220. 672 
63. Wickremasinghe, M. I., L. H. Thomas, and J. S. Friedland. 1999. Pulmonary 673 
epithelial cells are a source of IL-8 in the response to Mycobacterium tuberculosis: 674 
essential role of IL-1 from infected monocytes in a NF-kappa B-dependent network. 675 
Journal of Immunology 163:3936-3947. 676 
64. Winder, A. A., C. Wohlford-Lenane, and T. E. Scheetz. 2009. Differential effects of 677 
cytokines and corticosteroids on Toll-like receptor 2 expression and activity in human 678 
airway epithelia. Respiratory Research 10. 679 
65. Witzenrath, M., F. Pache, D. Lorenz, U. Koppe, B. Gutbier, C. Tabeling, K. Reppe, 680 
K. Meixenberger, A. Dorhoi, J. Ma, A. Holmes, G. Trendelenburg, M. M. 681 
Heimesaat, S. Bereswill, M. van der Linden, J. Tschopp, T. J. Mitchell, N. Suttorp, 682 
and B. Opitz. The NLRP3 Inflammasome Is Differentially Activated by Pneumolysin 683 
Variants and Contributes to Host Defense in Pneumococcal Pneumonia. J Immunol 684 
187:434-440. 685 
 32
66. Xu, F., D. Droemann, J. Rupp, H. Shen, X. Wu, T. Goldmann, S. Hippenstiel, P. 686 
Zabel, and K. Dalhoff. 2008. Modulation of the inflammatory response to Streptococcus 687 
pneumoniae in a model of acute lung tissue infection. American Journal of Respiratory 688 
Cell and Molecular Biology 39:522-529. 689 
67. Zwijnenburg, P. J., T. van der Poll, S. Florquin, J. J. Roord, and A. M. Van Furth. 690 
2003. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense 691 
against pneumococcal meningitis. J Immunol 170:4724-4730.  692 
 33
Figure legends 693 
Figure 1. Presence of macrophages enhances epithelial cell CXCL8 production. A-B) A549 694 
epithelial cells were either mock infected (white bars) or challenged with encapsulated (pale grey 695 
bars) or unencapsulated (dark grey bars) non-opsonized serotype 2 (A) and serotype 4 (B) S. 696 
pneumoniae (MOI 10) or IL-1β (black bars). CXCL8 levels in the cell-culture supernatants were 697 
measured by ELISA at the indicated time points. n=4-6.  C-D) A549 epithelial cells alone (EC), 698 
THP-1 cells alone (MC), and A549-THP-1 co-cultures (Co) were challenged with opsonized S. 699 
pneumoniae for up to 24 h. CXCL8 levels in the cell-culture supernatants were measured by 700 
ELISA at 2, 6, and 24 h time points. C) encapsulated (D39) and unencapsulated (FP22) serotype 701 
2 pneumococci n=7, D) encapsulated (TIGR4) and unencapsulated (FP23) serotype 4 702 
pneumococci n=5. Mock-infected (MI) and IL-1β data at the 24 h time point is shown for 703 
comparison.  One-way ANOVA (all p < 0.05) with Bonferroni's post-test, * p < 0.05; ** p < 704 
0.01, # p < 0.05 for CXCL8 level in co-culture vs. the sum of CXCL8 levels from A549 and 705 
THP-1 cells alone). 706 
 707 
Figure 2. Physical separation of macrophages from epithelial cells does not impair priming 708 
of CXCL8 production.  A549 epithelial cells alone (EC), THP-1 cells alone (MC), A549-THP-1 709 
co-cultures (Co), and A549 and THP-1 cells separated by transwells (TW) were challenged with 710 
D39 pneumococci (MOI 10). CXCL8 levels in the cell-culture supernatants were measured by 711 
ELISA at 6 h. IL-1β (positive control) data is shown for comparison (IL-1β). One-way ANOVA 712 
with Bonferroni's post-test, n=6, ns-not significant. 713 
 714 
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Figure 3. Conditioned media from THP-1 cells challenged with pneumococci primes 715 
epithelial cell CXCL8 production.  THP-1 cells were exposed to either mock-infection or D39 716 
S. pneumoniae (MOI 100) for 24 h. Mock-infected macrophage conditioned media (MCM-MI) 717 
and D39-challenged macrophage conditioned media (MCM-D) were collected at 24 h. 718 
Monolayers of A549 epithelial cells were then incubated with: media alone (EC); MCM-MI; 719 
THP-1 cells and D39 (MOI 10) (Co+D); MCM-D; MCM-D plus IL-1Ra (MCM-D/IL-1Ra); 720 
MCM-D plus sTNF type 1 receptor (MCM-D/TNFR1); MCM-D plus both inhibitors (MCM-721 
D/Both); or IL-1β. CXCL8 levels in the cell-culture supernatants were measured by ELISA at 6 722 
h, n=3, one-way ANOVA  (p < 0.001) with Bonferroni's post-test, * p < 0.05; ** p < 0.01. 723 
 724 
Figure 4. IL-1Ra blocks enhancement of CXCL8 production in co-cultures.  Monolayers of 725 
A549 epithelial cells alone (EC), THP-1 cells alone (MC), A549-THP-1 co-cultures (Co), co-726 
cultures with IL-1Ra (Co/IL-1Ra), co-cultures with sTNF type 1 receptor (Co/TNFR1), and co-727 
cultures with both inhibitors (Co/both) were challenged with A) encapsulated D39 and B) 728 
unencapsulated FP22 serotype 2 pneumococci, C) encapsulated TIGR4 and D) unencapsulated 729 
FP23 serotype 4 pneumococci. IL-1β-stimulated co-cultures are also shown for comparison. 730 
CXCL8 levels in the cell-culture supernatants were measured by ELISA at 6 h, n=3-4, one-way 731 
ANOVA (all p < 0.002) with Bonferroni's post-test, * p < 0.05; ** p < 0.01; *** p < 0.001. 732 
 733 
Figure 5. Enhanced epithelial cell CXCL8 production is also seen in co-cultures containing 734 
primary monocyte-derived macrophages.  A549 epithelial cells alone (EC), monocyte-derived 735 
macrophages alone (MDM), and A549-MDM co-cultures (Co) were challenged with opsonized 736 
S. pneumoniae A) D39 or B) TIGR4 (MOI 10), with or without IL-1 receptor antagonist (IL-737 
 35
1Ra) for 6 h, and CXCL8 levels in the cell-culture supernatants were measured by ELISA and 738 
normalised for cell number (data shows release/1x105 A549 cells).  Mock-infected (MI) and IL-739 
1β data are shown for comparison.  One-way ANOVA (all p < 0.05) with Bonferroni's post-test. 740 
*p < 0.05, ***p<0.01. p<0.01 for CXCL8 levels in co-culture vs. the sum of CXCL8 levels from 741 
A549 cells and MDM alone, n=3-5 from 3 independent experiments.  742 
 743 
Figure 6. IL-1β but not TNFα levels are enhanced in co-cultures following challenge with 744 
pneumococci.  A549 epithelial cells (EC) were exposed to media alone (-) or D39 pneumococci 745 
(+) as were THP-1 cells (MC) and A549-THP-1 co-cultures (Co) and A) IL-1β and B) TNFα 746 
levels measured by ELISA at 6 and 24 h, n=3, one-way ANOVA (all p < 0.02) with Bonferroni's 747 
post test, * p < 0.05. A549 epithelial cells were exposed to conditioned media from D39 748 
challenged THP-1 cells and C) IL-1β and D) TNFα levels were measured by ELISA at 0, 2, 6 749 
and 24 h. 750 
 751 
Figure 7. Modulation of IL-1 signalling alters production of CXC chemokines and 752 
polymorphonuclear cell (PMN) recruitment during S. pneumoniae infection in vivo.   753 
A) Percentage PMNs in bronchial alveolar lavage (BAL) from C57BL/6 control mice and mice 754 
deficient in IL-1 type 1 receptor on a C57BL/6 background (IL-1R1-/-) 24h after intratracheal 755 
instillation of 5x105 CFU type 4 pneumococci; Levels of B) CXCL1 and C) CXCL2 in BAL 756 
from the same experiment as A; D) Percentage PMNs in BAL from BALB/c control mice and 757 
mice deficient in IL-1 type receptor on a BALB/c background (IL-1R-/-) challenged with 758 
pneumocci as in A); Levels of E) CXCL1 and F) CXCL2 in BAL from the same experiment as 759 
D.(* p<0.05, ** p<0.01 unpaired t test.) 760 
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 761 
Figure 8. Modulation of IL-1 signaling can reduce the severity of invasive disease in 762 
fulminant pneumococcal infection.  A) Percentage neutrophils (PMN) in bronchial alveolar 763 
lavage (BAL) from BALB/c control mice and mice deficient in IL-1 type 1 receptor on a 764 
BALB/c background (IL-1R1-/-) 24h after intratracheal instillation of 1x107 CFU type 4 765 
pneumococci; Levels of B) CXCL1, C) CXCL2, and D) TNFα in BAL from the same 766 
experiment as A); CFU of bacteria in E) lung homogenates and F) blood in the same experiments 767 
as A. (* p<0.05 unpaired t test, **p<0.01 Mann Whitney). 768 








